---
title: "Dizal's ZEGFROVY® (Sunvozertinib) Shows Profound Antitumor Activity as First-Line Treatment in Advanced NSCLC Patients with PACC or Other Uncommon Mutations at ELCC 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280795792.md"
description: "Dizal's ZEGFROVY® (Sunvozertinib) demonstrated an 81.3% objective response rate as a first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with EGFR PACC or other uncommon mutations. The treatment showed a favorable safety profile, indicating its potential as a promising option. This data was presented at ELCC 2026 and disclosed on March 27, 2026. Dizal is listed on the Shanghai Stock Exchange under the symbol SSE:688192."
datetime: "2026-03-27T12:41:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280795792.md)
  - [en](https://longbridge.com/en/news/280795792.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280795792.md)
---

# Dizal's ZEGFROVY® (Sunvozertinib) Shows Profound Antitumor Activity as First-Line Treatment in Advanced NSCLC Patients with PACC or Other Uncommon Mutations at ELCC 2026

In a recent study, ZEGFROVY® as a primary treatment option showed an impressive 81.3% objective response rate among individuals with advanced non-small cell lung cancer (NSCLC) possessing EGFR PACC or less common genetic mutations. This demonstrates the drug's notable efficacy in this specific patient population. The treatment also exhibited a favorable safety profile making it a promising option for these patients. The study was conducted by Dizal, a biopharmaceutical company based in Shanghai. This data was disclosed on March 27, 2026, and the company is listed on the Shanghai Stock Exchange under the symbol SSE:688192.

### Related Stocks

- [688192.CN](https://longbridge.com/en/quote/688192.CN.md)

## Related News & Research

- [12:45 ETDizal to Report Key Progress in its NSCLC Portfolio with Two Oral Presentations and a Poster During ASCO 2026](https://longbridge.com/en/news/283537597.md)
- [Dizal’s Phase III NSCLC trial of Zegfrovy meets primary endpoint](https://longbridge.com/en/news/280237515.md)
- [BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models](https://longbridge.com/en/news/286973840.md)
- [Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights | PPBT Stock News](https://longbridge.com/en/news/286556016.md)
- [Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus | OTLC Stock News](https://longbridge.com/en/news/286276734.md)